A combination of 5-azacytidine and all-trans retinoic acid (ATRA) increased expression of nuclear receptor subfamily 2 Group F member 1 (NR2F1) maintaining dormancy via SOX9 and retinoic acid receptor (RAR)β in prostate cancer and HNSCC [84, 85]. This evidence concerns the gene NR2F1 and prostate cancer.